OnKure Therapeutics, Inc.
- OKUR
- NASDAQ
- Biotechnology
- Precision Oncology
- HDAC Inhibitors
$2.25
Today +7.14%Quote Oct 19, 2026, 08:00 PM UTC
−23.73%over the last month
Max drawdown −32.3%From 1-month high −27.4%3 months −46.0%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About OnKure Therapeutics
OnKure, Inc., established in 2011 and based in Boulder, Colorado, operates as a biopharmaceutical company primarily engaged in the creation and advancement of precise therapeutic agents for cancer. A core area of their research centers on developing highly selective inhibitors for histone deacetylases.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
45
Market value
$91.1M
Quote Oct 19
Analyst target
$14.00
+522.2% from here
Floor
$2.19
2.5% below price
Resistance
$2.38
5.6% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about OKURPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free